English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  Although APOBEC-mutational signature is found in tumor tissues of multiple cancers, how a common germline  APOBEC3A/B  deletion affects the mutational signature remains unclear.    Methods  Using data from 10 cancer types generated as part of TCGA, we performed integrative genomic and association analyses to assess inter-relationship of expressions for isoforms  APOBEC3A  and  APOBEC3B , APOBEC-mutational signature, germline  APOBEC3A/B  deletions, neoantigen loads, and tumor infiltration lymphocytes (TILs).    Results  We found that expression level of the isoform uc011aoc transcribed from the  APOBEC3A/B  chimera was associated with a greater burden of APOBEC-mutational signature only in breast cancer, while germline  APOBEC3A/B  deletion led to an increased expression level of uc011aoc in multiple cancer types. Furthermore, we found that the deletion was associated with elevated APOBEC-mutational signature, neoantigen loads and relative composition of T cells (CD8+) in TILs only in breast cancer. Additionally, we also found that APOBEC-mutational signature significantly contributed to neoantigen loads and certain immune cell abundances in TILs across cancer types.    Conclusions  These findings reveal new insights into understanding the genetic, biological and immunological mechanisms through which  APOBEC  genes may be involved in carcinogenesis, and provide potential genetic biomarker for the development of disease prevention and cancer immunotherapy.

bmc medical genomics

Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types